DEXAMETHASONE CAN POTENTIATE THE ANTI-EMETIC ACTION OF A 5HT3 RECEPTOR ANTAGONIST ON CYCLOPHOSPHAMIDE INDUCED VOMITING IN THE FERRET

被引:45
作者
HAWTHORN, J
CUNNINGHAM, D
机构
[1] ROYAL MARSDEN HOSP,INST CANC RES,MED SECT,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND
[2] ST GEORGE HOSP,SCH MED,DEPT PHYSIOL,LONDON SW17 0RE,ENGLAND
关键词
D O I
10.1038/bjc.1990.12
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A new group of selective 5HT3 antagonists are proving to be effective anti-emetics for cytotoxic and radiation induced vomiting in both animal models and man. Current anti-emetic regimens often benefit from combination therapy, in particular the efficacy of metoclopramide (which can be a weak 5HT3antagonist), can be improved by combination with dexamethasone, another anti-emetic. Hence it was of interest to evaluate whether a 5HT3 receptor antagonist GR38032F could be improved by combination with dexamethasone. Vomiting induced by cyclophosphamide in the ferret was observed after pre-treatment with dexamethasone alone or in combination with GR38032F. Animals were also observed for signs of ‘nausea’. Dexamethasone alone proved a weak anti-emetic in this system but did have significant effects on ‘nausea’. GR38032F has previously been shown to be capable of totally controlling emesis due to cyclophosphamide in the ferret. Here a dose of GR38032F that is not 100% effective was employed; this was shown to have effects on ‘nausea’ but most interestingly its anti-emetic action was increased by combination with dexamethasone. This may be important for the minority of patients whose vomiting is not completely controlled by GR38032F alone. © Macmillan Press Ltd., 1990.
引用
收藏
页码:56 / 60
页数:5
相关论文
共 34 条
  • [1] AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11
  • [2] DEXAMETHASONE AND HIGH-DOSE METOCLOPRAMIDE - EFFICACY IN CONTROLLING CISPLATIN INDUCED NAUSEA AND VOMITING
    ALLAN, SG
    CORNBLEET, MA
    WARRINGTON, PS
    GOLLAND, IM
    LEONARD, RCF
    SMYTH, JF
    [J]. BRITISH MEDICAL JOURNAL, 1984, 289 (6449) : 878 - 879
  • [3] EVIDENCE FOR AN EXTRA-ABDOMINAL SITE OF ACTION FOR THE 5-HT3 RECEPTOR ANTAGONIST BRL24924 IN THE INHIBITION OF RADIATION-EVOKED EMESIS IN THE FERRET
    ANDREWS, PLR
    HAWTHORN, J
    [J]. NEUROPHARMACOLOGY, 1987, 26 (09) : 1367 - 1370
  • [4] THE ANTI-EMETIC POTENTIAL OF THE 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONIST BRL-43694
    BERMUDEZ, J
    BOYLE, EA
    MINER, WD
    SANGER, GJ
    [J]. BRITISH JOURNAL OF CANCER, 1988, 58 (05) : 644 - 650
  • [5] BOYLE EA, 1987, BRIT J CANCER, V56, P227
  • [6] BRITTAIN R T, 1987, British Journal of Pharmacology, V90, p87P
  • [7] BRUERA ED, 1983, CANCER TREAT REP, V67, P381
  • [8] THE SEROTONIN TYPE-3 RECEPTOR ANTAGONIST BRL-43694 AND NAUSEA AND VOMITING INDUCED BY CISPLATIN
    CARMICHAEL, J
    CANTWELL, BMJ
    EDWARDS, CM
    RAPEPORT, WG
    HARRIS, AL
    [J]. BRITISH MEDICAL JOURNAL, 1988, 297 (6641) : 110 - 111
  • [9] RADIATION-INDUCED EMESIS IN THE DOG - EFFECTS OF LESIONS AND DRUGS
    CARPENTER, DO
    BRIGGS, DB
    KNOX, AP
    STROMINGER, NL
    [J]. RADIATION RESEARCH, 1986, 108 (03) : 307 - 316
  • [10] ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY
    COATES, A
    ABRAHAM, S
    KAYE, SB
    SOWERBUTTS, T
    FREWIN, C
    FOX, RM
    TATTERSALL, MHN
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02): : 203 - 208